Pain106(2003)169–172
www.elsevier.com/locate/pain
Lack of analgesic efficacy of oral d-9-tetrahydrocannabinol in
postoperative pain
Donal J. Buggyb, Lynn Toogooda, Shelagh Marica, Paul Sharpea, David G. Lamberta,
David J. Rowbothama,*
aDepartmentofAnaesthesia,CriticalCareandPainManagement,UniversityofLeicester&UniversityHospitalsofLeicesterNHSTrust,
LeicesterRoyalInfirmary,LeicesterLE15WW,UK
bMaterMisericordiaeHospital,Dublin,Ireland
Received12May2003;receivedinrevisedform23July2003;accepted31July2003
Abstract
Wehaveevaluatedtheefficacyofd-9-tetrahydrocannabinol(d-9-THC),themainpsychoactiveconstituentofcannabis,inpostoperative
pain. In a randomized double-blind, placebo-controlled, single-dose trial, we investigated 40 women undergoing elective abdominal
hysterectomy.Randomizationtookplacewhenpostoperativepatient-controlledanalgesiawasdiscontinuedonthesecondpostoperativeday.
Whenpatientsrequestedfurtheranalgesia,theyreceivedasingle,identicalcapsuleofeitherorald-9-THC5mgðn¼20Þorplaceboðn¼20Þ
inadouble-blindfashion.Theprimaryoutcomemeasurewassummedpainintensitydifference(SPID)at6hafteradministrationofstudy
medicationderivedfromvisualanaloguepainscoresonmovementandatrest.Secondaryoutcomemeasuresweretimetorescuemedication
andadverseeffectsofstudymedication.Mean(SD)VASpainscoresbeforemedicationintheplaceboandd-9-THCgroupswere6.3(2.6)
and6.4(1.3)cmonmovement,and3.2(1.9)and3.3(0.9)onrest,respectively.Therewerenosignificantdifferencesinmean(95%confidence
intervalofthedifference)SPIDat6hbetweenthegroups[placebo7.9,d-9-THC4.3(21.8to9.0)cmhonmovement;placebo8.8,d-9-THC
4.9(20.2 to 8.1)cmh at rest] and time to rescue analgesia [placebo 217, d-9-THC 163(222 to 130)min]. Increased awareness of
surroundingswasreportedmorefrequentlyinpatientsreceivingd-9-THC(40vs5%,P¼0:04).Therewerenoothersignificantdifferences
with respect to adverse events. This study demonstrates no evidence of an analgesic effect of orally administered d-9-THC 5mg in
postoperativepaininhumans.
q2003InternationalAssociationfortheStudyofPain.PublishedbyElsevierB.V.Allrightsreserved.
Keywords:Cannabinoids;d-9-Tetrahydrocannabinol;Pain;Postoperative;Randomizedcontroltrial
1. Introduction 15% confirmed that they had used cannabis for pain relief
(Ware et al., 2003).
There is significant evidence that cannabinoids have However,theevidence-baseforthe useofcannabinoids
antinociceptivepropertiesinanimals(MartinandLichtman, for pain relief is yet to be established. A recent qualitative
1998) and the role of cannabinoid receptors in the systematicreviewdescribedthepaucityofgoodqualitydata
modulation of pain has been described (Meng et al., from controlled clinical trials in this area (Campbell et al.,
1998). Anecdotal accounts of the benefits of cannabinoids 2001).
in the treatment of pain in humans are reported frequently d-9-Tetrahydrocannabinol (d-9-THC) is the main
(Hirstetal.,1998;Holdcroftetal.,1997;Ravenscroftetal., psychoactive constituent of cannabis (Ashton, 1999; Hirst
2000; Voth and Schwartz, 1997; Ware et al., 2003). For etal.,1998;KirkandDeWit,1999)andislicensedinsome
example, in a population of 209 chronic non-cancer pain
countries as an anti-emetic for chemotherapy and an
patients attending a pain management unit in Canada,
appetite stimulant in HIV (Voth and Schwartz, 1997). We
report the first randomized, double-blind, placebo-con-
* Corresponding author. Tel.: þ44-116-258-5291; fax: þ44-116-285-
trolled study investigating the analgesic efficacy of orally
4487.
administeredd-9-THC inpostoperative pain.
E-mailaddress:djr8@le.ac.uk(D.J.Rowbotham).
0304-3959/$20.00q2003InternationalAssociationfortheStudyofPain.PublishedbyElsevierB.V.Allrightsreserved.
doi:10.1016/S0304-3959(03)00331-2
170 D.J.Buggyetal./Pain106(2003)169–172
2. Methods 2.4.Statistical analysis
2.1. Participants Data were tested for normality with the Kolmogorov–
Smirnov test and compared using Student’s t-test,
With local Ethics Committee approval and written MANOVA for repeated measures and Fisher’s-exact test,
informed patient consent, patients (American Society of as appropriate. For calculation of the SPID, if a patient
Anesthesiologists classification I or II) scheduled for requested escape analgesia before the end of the 6-h study
elective total abdominal hysterectomy were recruited on period, subsequent pain intensity difference (PID) scores
admission to the Leicester Royal Infirmary and Leicester weresettozero.Thisisarecognizedtechniqueforhandling
General Hospital, UK. Patients with a history of drug or such data (Curtis et al., 1999). We used two sets ofdata to
alcohol abuse, previous cannabis use and past or present power the study. In a previous study performed in our
psychiatric illness were excluded. hospital investigating a similar group of patients receiving
morphine PCA after abdominal hysterectomy, the standard
deviationofVASpainscoreswas2.2cm(Alietal.,1998).
2.2. Design
Takinga2cmreductioninVASasclinicallysignificant,20
patients were required in each group for a¼0:05 and
General anesthesia was standardized. Induction was
b¼0:2:Also,usingdatafromastudy(Curtisetal.,1999)
with propofol 1–2mg/kg and atracurium 0.5mg/kg to
whichutilizedthesamepostoperativepainmodel(painafter
facilitate endotracheal intubation and positive pressure
hysterectomy)tomeasuretheefficacyoforalanalgesics,our
ventilation. Anesthesia was maintained with isoflurane
samplesizewouldbeabletodetectadifferenceinmeanPID
(1–2 MAC) in a 50% nitrous oxide–oxygen mixture and
of15mm (a¼0:05;b¼0:2).
morphine 0.1–0.2mg/kg. Patient-controlled analgesia
(PCA) using morphine (bolus dose 1mg, lockout-time
5min) was provided for the first 24 postoperative hours in
3.Results
all patients.
Randomization took place when PCA was discontinued
3.1.Demographic variables
on the second postoperative day and the patient requested
further analgesia. Patients were randomized to receive a
Fifty patients were consented forthe study,10 were not
single, identical capsule of either oral d-9-THC 5mg or
randomizedbecausetheydidnotfulfilltheinclusioncriteria
placebo in a double-blind fashion. Identical capsules were
at time of request for analgesia after PCA (four vaginal
prepared by the hospital pharmacy in coded tablet bottles
hysterectomy, two laparoscopic assisted procedure, two
usingarandomizationtable.Patientswereconsentedbefore
withdrawal of consent, one inability to tolerate oral fluids,
anesthesiabutwerenotrandomizedandinvestigatedifthey
oneinadvertentadministrationofsupplementaryanalgesia).
were unable to tolerate oral fluids or were complaining of
No patient withdrew from the study after randomization.
nauseaor vomiting.
The groups were well matched for age, weight and pain
scoresbeforeadministrationofstudymedication(Table1).
2.3. Measures
3.2.Painmeasures
Pain was recorded hourly for 6h and then at 8 and
24h using a 10-cm visual analogue scale (VAS) on After study medication, there were no differences in
movement (sitting forward and coughing) and at rest. The mean VAS pain scores (Table 2) or PID scores on
primary outcome measure ofthis study was the sum ofthe movement and at rest (Fig. 1). Data for 8 and 24h are not
pain intensity differences (SPID) on movement and at rest shown because the majority of patients received escape
over a 6-h period. A secondary outcome measure was analgesia by 8h (85% placebo, 100% d-9-THC). There
time to request for rescue analgesia (oral codeine 30mg). were no differences in mean SPID at 6h or time to rescue
Patients were able to ask for this at any time during the analgesia (Table 3).
study.
At each time point and at 24h after study medication, Table1
patients were asked to volunteer the nature and severity of Mean (SD) patient characteristics and baseline VAS pain scores. No
any adverse events. They were then asked if they significantdifferences
experienced any of the following specific symptoms: Placeboðn¼20Þ d-9-THCðn¼20Þ
increased awareness of surroundings, drowsiness, dry
mouth, dizziness, confusion, blurred or double vision, Age(yr) 47.8(10.2) 44.8(8.5)
palpitations, sense of well-being, change of mood, slurred Weight(kg) 61.1(9.8) 60.3(8.5)
BaselineVASmovement(cm) 6.3(2.6) 6.4(1.3)
speech, difficulty with memory, hallucinations, headache,
BaselineVASrest(cm) 3.2(1.9) 3.3(0.9)
tremorand muscle twitching.
D.J.Buggyetal./Pain106(2003)169–172 171
Table2 Table3
Mean(SD)VASpainscores(cm)andnumberofevaluablepatientsat0,2,4 Mean(SEM)and95%confidenceintervalofthedifferencesofsummedpain
and6h.Nosignificantdifferences intensitydifferencesover6h(SPID )(cmh)onmovementandatrest,and
6h
mean(SEM)timetorescueanalgesia(min).Nosignificantdifferences
0h 2h 4h 6h
Placebo d-9-THC 95%CIof
Placebo ðn¼20Þ ðn¼20Þ differences
Movement 6.3(2.6) 5.5(2.4) 5.7(2.0) 4.7(2.1)
Rest 3.2(1.9) 2.6(1.5) 2.8(1.4) 2.3(1.4) SPID moving(cmh) 7.9(2.5) 4.3(1.0) 21.8to9.0
6h
n¼20 n¼13 n¼8 n¼5 SPID atrest(cmh) 8.8(1.7) 4.9(1.2) 20.2to8.1
6h
Timetorescueanalgesia(min) 217(34) 163(17) 222to130
d-9-THC
Movement 6.4(1.3) 6.5(2.6) 6.1(2.1) 5.5(2.2)
Rest 3.3(0.9) 3.3(1.7) 3.0(1.4) 2.8(1.5)
Table4
n¼20 n¼15 n¼7 n¼4
Incidenceofadverseevents
Adverseevent Placebo,n(%) d-9-THC,n(%)
Increasedawarenessofsurroundings 1(5) 8(40)*
Drowsiness 19(95) 18(90)
Drymouth 15(75) 16(80)
Palpitations 5(25) 8(40)
Changeofmood 6(30) 8(40)
Difficultywithmemory 3(15) 2(10)
Slurringofspeech 2(10) 3(15)
Blurredvision 3(15) 2(10)
Dizziness 6(30) 5(25)
Hallucinations 1(5) 0(0)
Headache 10(50) 8(40)
Involuntarymuscletwitching 3(15) 3(15)
Tremor 2(10) 1(5)
Valuesshownarenumberofpatients(%)reportingspontaneously,or
ondirectquestioning,anadverseeventatanytimeupto24hafterstudy
medication.*P¼0:04:
4. Discussion
We have shown no significant effect of oral d-9-THC
5mgonaccumulativeVASpainscoresover6hinpatients
with postoperative pain. The confidence intervals of the
differences show that we are unlikely to have missed an
importantclinicallysignificantanalgesiceffectofd-9-THC.
The limit of the 95% confidence interval of the SPID on
movement over 6h in favor of d-9-THC was 1.8cm, an
average of 0.3cm/h. Indeed, there was a non-significant
tendencyforlesspainintheplacebogroup.Mean(SD)VAS
pain scores on movement before administration of study
medication (placebo 6.3(2.6)cm; d-9-THC 6.4(1.3)cm)
were sufficienttoensureadequate sensitivity of the study.
In 1975, it was suggested that 10mg of d-9-THC may
haveanalgesiceffectsinpatientswithadvancedcancerbut
the study was poorly controlled and relatively insensitive
Fig.1.Mean(SEM)VASpainintensitydifferences(A)atrestand(B)on (Noyesetal.,1975).Atthisdose,70%ofpatientsreported
movement.Nosignificantdifferences(MANOVAforrepeatedmeasures).
sedation, 32% mental clouding, 29% ataxia and 29%
‘disconnected thought’. This high incidence of adverse
3.3. Side-effects
events and the fact that the recommended starting dose of
d-9-THC for appetite stimulation is 2.5mgbd (Beal et al.,
There was a significant increase in the incidence of 1995),ledustochooseadoseof5mgforourstudy.Inacase
increasedawarenessofsurroundingsinthed-9-THCgroup report of a patient with abdominal pain associated with
(40 vs 5%, P,0:05) but no differences in other adverse familial Mediterranean fever, a higher dose was used but
events (Table 4). the patient was already obtaining pain relief by smoking
172 D.J.Buggyetal./Pain106(2003)169–172
cannabis and was receiving regular morphine (Holdcroft AliPB,CottonBR,WilliamsonKM,SmithG.Intraperitonealbupivacaine
etal.,1997). or lidocaine does not provide analgesia after total abdominal
hysterectomy.BrJAnaesth1998;80:245–7.
We did not measure blood concentrations of d-9-THC.
AshtonCH.Adverseeffectsofcannabisandcannabinoids.BrJAnaesth
However, there is little reason to suspect that it was not
1999;83:637–49.
absorbed,asonlypatientswhocouldtolerateoralfluidsand Beal JE, Olson R, Laubenstein L, Morales JO, Bellman P, Yangco B,
those who were not suffering from nausea and/or vomiting Lefkowitz L, Plasse TF, Shepard KV. Dronabinol as a treatment for
were recruited. Furthermore, studies of this design have anorexia associated with weight loss in patients with AIDS. J Pain
SymptomManage1995;10:89–97.
beenabletoshowsignificantanalgesiceffectsofotherdrugs
CampbellFA,TramerMR,CarrollD,ReynoldsDJ,MooreRA,McQuayHJ.
administered orally under identical circumstances (Curtis
Arecannabinoidsaneffectiveandsafetreatmentoptioninthemanagement
etal.,1999).Afteroraladministrationofd-9-THC,theonset ofpain?Aqualitative,systematicreview.BrMedJ2001;323:13–16.
ofactionisusuallywithin0.5–1hwithadurationofeffect CurtisGB,JohnsonGH,ClarkP,TaylorR,BrownJ,O’CallaghanR,Shi
of 4–6h. Therefore, our study period of 6h should have M, Lacouture PG. Relative potency of controlled-release oxycodone
andcontrolled-releasemorphineinapostoperativepainmodel.EurJ
been able to detect any analgesic effect. A recognized
ClinPharmacol1999;55:425–9.
adverseeffectofcannabinoidsuseisanincreasedawareness
Hirst RA, Lambert DG, Notcutt WG. Pharmacology and potential
of surroundings (Adams and Martin, 1996) and this was therapeuticusesofcannabis.BrJAnaesth1998;81:77–84.
reported by 40% of our patients who received d-9-THC HoldcroftA,SmithM,JacklinA,HodgsonH,SmithB,NewtonM,Evans
(placebo 5%). F.PainreliefwithoralcannabinoidsinfamilialMediterraneanfever.
Anaesthesia1997;52:483–6.
In conclusion, we have shown that oral d-9-THC 5mg
Kirk JM, De Wit H. Responses to oral delta-9-tetrahydrocannabinol in
was ineffective for postoperative pain in the conditions of
frequent and infrequent marijuana users. Pharmacol Biochem Behav
ourstudy.Furtherinvestigationofalargerdoseorrepeated 1999;63:137–42.
administration may be warranted, but this has been MartinBR,LichtmanAH.Cannabinoidtransmissionandpainperception.
associated with a high incidence of side-effects (Noyes NeurobiolDis1998;5:447–61.
Meng ID, Manning BH, Martin WJ, Fields HL. An analgesia circuit
et al., 1975). Data on the effect of other cannabinoids for
activatedbycannabinoids.Nature1998;395:381–3.
postoperative pain are lacking.
NoyesR,BrunkSF,AveryDH,CanterA.Theanalgesicpropertiesofdelta-9-
tetrahydrocannabinolandcodeine.ClinPharmacolTher1975;18:84–9.
RavenscroftA,AhmedYS,BurnsideIG.ChronicpainafterSCI.Apatient
survey.SpinalCord2000;38:611–4.
Voth EA, Schwartz RH. Medicinal applications of delta-9-tetrahydro-
References
cannabinolandmarijuana.AnnInternMed1997;126:791–8.
WareMA,DoyleCR,WoodsR,LynchME,ClarkAJ.Cannabisusefor
AdamsIB,MartinBR.Cannabis:pharmacologyandtoxicologyinanimals chronicnon-cancerpain:resultsofaprospectivesurvey.Pain2003;102:
andhumans.Addiction1996;91:1585–614. 211–6.
